The Indian Pharmaceutical industry – with a market size of INR1 lakh crore (as of 2016) – faces a loss of approximately INR10,000 crore due to the unforeseen ban of 344 Fixed Dose Combination (FDC) Drugs by the government. The ban discontinues the sale and manufacture of popular brands like Vicks Action 500 Extra – from Procter & Gamble (P&G) – a Fast-Moving Consumer Goods (FMCG), among others. Pharma giants Abbott, Pfizer and Macleods Pharma have urged a stay or lifting of the ban. With 1,000 cases under scrutiny, the industry is bound to see more legal battles. FDC drugs are banned in UK and the US due to health risks they pose such as anti-microbial resistance and even organ failure. How will India’s Pharma market pick itself up from the FDC drugs ban? https://www.spireresearch.com/newsroom/spirethoughts/indian-pharma-industry-hit-by-ban-on-fdc-drugs/